Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Salomon Manier

Salomon Manier

MD, PhD
Lille Hospital University
IFM2021-01 trial Cohort A: teclistamab + daratumumab in older patients with newly diagnosed myeloma 2:14
IFM2021-01 trial Cohort A: teclistamab + daratumumab in older patients with newly diagnosed myeloma
Salomon Manier • 7 Dec 2025
Results of IFM2017-03: dexamethasone-sparing regimen in frail patients with newly diagnosed myeloma 2:45
Results of IFM2017-03: dexamethasone-sparing regimen in frail patients with newly diagnosed myeloma
Salomon Manier • 7 Dec 2024
Ongoing CAR-T trials in earlier lines of therapy in myeloma & strategies to improve efficacy 1:54
Ongoing CAR-T trials in earlier lines of therapy in myeloma & strategies to improve efficacy
Salomon Manier • 9 Jun 2023
Impact of prior BCMA-directed therapy on the efficacy of elranatamab in R/R multiple myeloma 1:52
Impact of prior BCMA-directed therapy on the efficacy of elranatamab in R/R multiple myeloma
Salomon Manier • 9 Jun 2023
KarMMa-3 subgroup analysis: ide-cel vs standard regimens in triple-class exposed myeloma 1:55
KarMMa-3 subgroup analysis: ide-cel vs standard regimens in triple-class exposed myeloma
Salomon Manier • 9 Jun 2023
Determining the optimal sequencing of bispecifics and CAR-T cells in patients with myeloma 3:33
Determining the optimal sequencing of bispecifics and CAR-T cells in patients with myeloma
Salomon Manier • 13 May 2023
Sequencing BCMA-targeted agents in multiple myeloma 2:19
Sequencing BCMA-targeted agents in multiple myeloma
Salomon Manier • 27 Aug 2022
Treatment strategies for frail and elderly myeloma patients 1:34
Treatment strategies for frail and elderly myeloma patients
Salomon Manier • 27 Aug 2022
Optimal strategies to manage late-stage multiple myeloma: the promise of anti-BCMA therapies 3:15
Optimal strategies to manage late-stage multiple myeloma: the promise of anti-BCMA therapies
Salomon Manier • 27 Aug 2022
Primary refractory young myeloma: a difficult clinical situation 4:32
Primary refractory young myeloma: a difficult clinical situation
Salomon Manier • 8 May 2020
Molecular prognostication in SMM 3:28
Molecular prognostication in SMM
Salomon Manier • 8 May 2020
The content of VJHemOnc is intended for healthcare professionals